Stay updated on Ipilimumab and Nivolumab for Liver Metastatic Uveal Melanoma Clinical Trial

Sign up to get notified when there's something new on the Ipilimumab and Nivolumab for Liver Metastatic Uveal Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ipilimumab and Nivolumab for Liver Metastatic Uveal Melanoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the clinical trial study details for the phase II trial studying ipilimumab and nivolumab with immunoembolization in treating patients with metastatic uveal melanoma that has spread to the liver.
    Difference
    0.1%
    Check dated 2024-06-06T14:20:39.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to a detailed description of eligibility criteria, explaining that researchers look for people who fit specific descriptions based on factors like general health condition or prior treatments. The new text also provides an example of inclusion criteria for a clinical study on metastatic uveal melanoma in the liver.
    Difference
    33%
    Check dated 2024-05-22T20:31:03.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T21:51:01.000Z thumbnail image

Stay in the know with updates to Ipilimumab and Nivolumab for Liver Metastatic Uveal Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ipilimumab and Nivolumab for Liver Metastatic Uveal Melanoma Clinical Trial page.